Roivant Sciences has crossed from a cash-rich clinical holding company into a commercial immunology platform after the late-August approval of LISRAYA, the first targeted oral therapy for adult dermatomyositis. The June quarter itself was the quiet interval the chief executive described: almost no product revenue, a widening operating loss, and a balance sheet still carrying the Genevant settlement receivable that arrived in July. The investment debate is whether the market is paying for a multi-indication oral franchise and a separately listed FcRn pipeline, or for a first-product launch that cannot yet support an enterprise value near $26 billion.
The tension sits in the capital account rather than the income statement. Consolidated cash and marketable securities sat at $3.9 billion at mid-year, before Genevant collected its share of the Moderna fixed payment. That liquidity funds the Priovant launch, Immunovant's six-indication anti-FcRn program, and Pulmovant's inhaled cardiopulmonary study without an immediate equity raise. The quarter's buybacks totaled $209 million. The counterargument is that adjusted net loss widened as program spend accelerated, so the cash pile is being consumed at a faster rate just as commercial infrastructure comes online.
LISRAYA is now on the market with a boxed JAK-class warning and a specialty-pharmacy launch that management framed as slow and steady rather than a first-year sales sprint. Net loss attributable to the parent narrowed to $190 million even as consolidated operating expenses rose. The next several months resolve whether dermatomyositis uptake, the non-infectious uveitis registrational readout, and Immunovant's rheumatoid-arthritis update justify the multiple, or whether the equity remains a sum-of-parts cash-plus-options story that still needs clinical confirmation.